

<b>SUSPECT ADVERSE REACTION REPORT</b>  2025-AER-030667												

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) Unknown	1a. COUNTRY PANAMA	2. DATE OF BIRTH			2a. AGE Years 80	3. SEX Male	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input checked="" type="checkbox"/> PATIENT DIED <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION <input type="checkbox"/> RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER MEDICALLY IMPORTANT CONDITION
		Day	Month	Year			Day	Month	Year	
7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) 1) Grade IV anemia (Anemia (10002272), Anaemia (10002034)) Fatal 2) Cancer (Malignant neoplasm progression (10051398), Malignant neoplasm progression (10051398)) Fatal										

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) 1) Enzalutamide (Enzalutamide, Enzalutamide) (Suspect) (Unknown) (Unknown)		20. DID EVENT ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA  21. DID EVENT REAPPEAR AFTER REINTRODUCTION <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA (NA : Not Applicable)
15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION 1) Unknown	
17. INDICATION(S) FOR USE 1) Advanced metastatic castration-resistant prostate cancer [10076506 - Castration-resistant prostate cancer]		
18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) No concomitants used/reported
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Name : Astellas Pharma Global Development, Inc. 2375 Waterview Drive Northbrook, IL, 60062-6111, UNITED STATES OF AMERICA		
24. REPORT NULLIFIED <input type="checkbox"/> YES <input type="checkbox"/> NO	24b. MFR CONTROL NO. 2025-AER-030667	
24c. DATE RECEIVED BY MANUFACTURER 30/May/2025	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL	
DATE OF THIS REPORT 05/Jun/2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP	

= Continuation attached sheet(s)..

## Continuation Sheet for CIOMS report

## 7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

## Event Description :

This spontaneous case was received by Astellas business partner Pfizer, on 30-May-2025, from a physician in PANAMA and was received at Astellas from Pfizer on 04-Jun-2025, concerning an 80 Year(s) old Male patient, who was on Enzalutamide, Unknown. Indication for use was Castration-resistant prostate cancer.

The patient received enzalutamide for advanced metastatic castration-resistant prostate cancer according to the following dosage regimen: (start date not provided) - (stop date not provided), unknown route, dose and frequency.

The patient received talazoparib for advanced metastatic castration-resistant prostate cancer according to the following dosage regimen: (start date not provided) - (stop date not provided), unknown route, dose and frequency.

Action taken with enzalutamide and talazoparib in response to the events was Not applicable.

The doctor stated that the patient developed grade IV anemia, which required multiple transfusions. Unfortunately, the patient died from the cancer. The reported cause of death was grade IV anemia and cancer. It is unknown if autopsy was performed. Death certificate was not available.

Medical history was not reported.

Past medications were not reported.

Concomitant medications were not reported.

No relevant lab data was reported.

The Physician assessed the following events with respect to enzalutamide and talazoparib: -  
 - Grade IV anemia (seriousness: Serious (Death); causality: Not assessed)  
 - Cancer (seriousness: Serious (Death); causality: Not assessed)

Consent to contact Physician for follow-up information was denied. No additional information available.

## Tracking of changes:

30-May-2025: Initial information was received.

## Company Remarks (Sender's Comments) :

## Event Information:

Anemia and Malignant neoplasm progression were assessed as Serious due to Death.

Grade IV anemia was coded as Anemia and Cancer was coded as Malignant neoplasm progression due to closest available LLTs in MedDRA.

## Product: Enzalutamide

Astellas assessed Malignant neoplasm progression as Not Related, since progression is inherent to the nature of underlying malignancy. Anemia was assessed as Not Related, as based on the information available, a reasonable possibility to suggest a relationship between the suspect drug and the event cannot be established. Elderly aged patient with underlying advanced metastatic malignancy was the risk factor.

## 14.SUSPECT DRUG(S) (Continuation...)

## Product-Reaction Level

1) Drug	: Enzalutamide (Enzalutamide)
Active Substance	: 1) Enzalutamide
Drug Characterization	: Suspect
Form of Admin	: 1) Unknown
Lot Number	: 1) Unknown
Route of Admin	: 1) Unknown
Indications	: 1) Advanced metastatic castration-resistant prostate cancer [10076506 - Castration-resistant prostate cancer]
Action(s) Taken With Drug	: Not applicable

## Causality

1) Grade IV anemia (Anemia - 10002272, Anaemia - 10002034 )	
Causality as per reporter	: Not assessed
Causality as per Mfr	: Not Related
DeChallenge	: Not applicable

## Continuation Sheet for CIOMS report

ReChallenge : Not Applicable  
 2) Cancer (Malignant neoplasm progression - 10051398, Malignant neoplasm progression - 10051398 )  
 Causality as per reporter : Not assessed  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable

## Labeling :

1) Grade IV anemia  
 CORE UnLabeled  
 IB UnLabeled  
 2) Cancer  
 CORE UnLabeled  
 IB UnLabeled

2) Drug : Talazoparib  
 Active Substance : 1) TALAZOPARIB  
 Drug Characterization : Suspect  
 Form of Admin : 1) Unknown  
 Lot Number : 1) Unknown  
 Route of Admin : 1) Unknown  
 Indications : 1) Advanced metastatic castration-resistant prostate cancer [10076506 - Castration-resistant prostate cancer]  
 Action(s) Taken With Drug : Not applicable

## Causality

1) Grade IV anemia (Anemia - 10002272, Anaemia - 10002034 )  
 Causality as per reporter : Not assessed  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable  
 2) Cancer (Malignant neoplasm progression - 10051398, Malignant neoplasm progression - 10051398 )  
 Causality as per reporter : Not assessed  
 Causality as per Mfr : Not Related  
 DeChallenge : Not applicable  
 ReChallenge : Not Applicable